GlassScriptPhysician profile
Janette Mcdougall
NPI 1134764012
$5,765.62
in general payments reported to CMS, 2019-2025
31 companies · $1,860 in 2025
The $1,860 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $830 · 2022: $1,105 · 2023: $623 · 2024: $1,346 · 2025: $1,860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,561 · Consulting Fee: $152 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,561.11 |
| Consulting Fee | $151.78 |
| Education | $116.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,197.78 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $703.30 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $608.60 | 2021-2025 | Hyqvia, Takhzyro, Eohilia |
| Biocryst US Sales Co., LLC | $417.66 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $393.11 | 2021-2025 | Ruconest |
| Novartis Pharmaceuticals Corporation | $271.56 | 2021-2025 | |
| Octapharma USA, INC. | $229.28 | 2021-2023 | Cutaquig |
| Astrazeneca Pharmaceuticals LP | $211.89 | 2021-2025 | Airsupra, Fasenra |
| Kaleo, INC. | $188.52 | 2021-2024 | Auvi-Q |
| Adma Biomanufacturing LLC | $151.78 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $141.53 | 2025 | Neffy |
| Abbvie INC. | $112.87 | 2025 | |
| Genzyme Corporation | $106.23 | 2022-2025 | |
| Optinose US, INC. | $99.94 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $99.08 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $96.30 | 2025 | Sajazir |
| Csl Behring | $95.72 | 2021-2024 | Haegarda |
| Teva Pharmaceuticals USA, INC. | $85.64 | 2021 | |
| Alk-Abello, INC | $80.49 | 2022-2025 | Pre-Pen, Alternaria Tenuis, Timothy, Standardized |
| Bio Products Laboratory USA, INC. | $76.45 | 2022-2023 | Gammaplex, Coagadex |
| Ionis Pharmaceuticals, INC. | $68.20 | 2025 | Dawnzera |
| Pfizer INC. | $66.64 | 2021-2023 | |
| Grifols USA, LLC | $54.61 | 2022-2024 | Xembify |
| Baxter Healthcare | $52.43 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $39.89 | 2022-2024 | Tezspire |
| Genentech USA, INC. | $28.08 | 2025 | Xolair |
| Horizon Therapeutics Plc | $23.16 | 2022 | |
| Leo Pharma INC. | $22.20 | 2022 | |
| Lilly USA, LLC | $17.21 | 2025 | Taltz, Ebglyss |
| Allergan, INC. | $12.96 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janette Mcdougall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.